↓ Skip to main content

Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator

Overview of attention for article published in Molecular Neurodegeneration, July 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
1 news outlet
twitter
1 X user
patent
2 patents

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator
Published in
Molecular Neurodegeneration, July 2015
DOI 10.1186/s13024-015-0021-z
Pubmed ID
Authors

Joo In Jung, Ashleigh R. Price, Thomas B. Ladd, Yong Ran, Hyo-Jin Park, Carolina Ceballos-Diaz, Lisa A. Smithson, Günther Hochhaus, Yufei Tang, Rajender Akula, Saritha Ba, Edward H. Koo, Gideon Shapiro, Kevin M. Felsenstein, Todd E. Golde

Abstract

Amyloid-β (Aβ) 42 has been implicated as the initiating molecule in the pathogenesis of Alzheimer's disease (AD); thus, therapeutic strategies that target Aβ42 are of great interest. γ-Secretase modulators (GSMs) are small molecules that selectively decrease Aβ42. We have previously reported that many acidic steroids are GSMs with potencies ranging in the low to mid micromolar concentration with 5β-cholanic acid being the most potent steroid identified GSM with half maximal effective concentration (EC50) of 5.7 μM. We find that the endogenous cholesterol metabolite, 3β-hydroxy-5-cholestenoic acid (CA), is a steroid GSM with enhanced potency (EC50 of 250 nM) relative to 5β-cholanic acid. CA i) is found in human plasma at ~100-300 nM concentrations ii) has the typical acidic GSM signature of decreasing Aβ42 and increasing Aβ38 levels iii) is active in in vitro γ-secretase assay iv) is made in the brain. To test if CA acts as an endogenous GSM, we used Cyp27a1 knockout (Cyp27a1-/-) and Cyp7b1 knockout (Cyp7b1-/-) mice to investigate if manipulation of cholesterol metabolism pathways relevant to CA formation would affect brain Aβ42 levels. Our data show that Cyp27a1-/- had increased brain Aβ42, whereas Cyp7b1-/- mice had decreased brain Aβ42 levels; however, peripheral dosing of up to 100 mg/kg CA did not affect brain Aβ levels. Structure-activity relationship (SAR) studies with multiple known and novel CA analogs studies failed to reveal CA analogs with increased potency. These data suggest that CA may act as an endogenous GSM within the brain. Although it is conceptually attractive to try and increase the levels of CA in the brain for prevention of AD, our data suggest that this will not be easily accomplished.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 42 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 19%
Student > Master 7 17%
Student > Ph. D. Student 5 12%
Student > Bachelor 3 7%
Lecturer > Senior Lecturer 2 5%
Other 7 17%
Unknown 10 24%
Readers by discipline Count As %
Agricultural and Biological Sciences 8 19%
Neuroscience 7 17%
Biochemistry, Genetics and Molecular Biology 4 10%
Chemistry 4 10%
Medicine and Dentistry 4 10%
Other 6 14%
Unknown 9 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2022.
All research outputs
#1,889,761
of 22,817,213 outputs
Outputs from Molecular Neurodegeneration
#183
of 848 outputs
Outputs of similar age
#25,728
of 262,658 outputs
Outputs of similar age from Molecular Neurodegeneration
#4
of 20 outputs
Altmetric has tracked 22,817,213 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 848 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.2. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,658 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.